| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we evaluated the pharmacokinetic models of meropenem among critically ill patients. The best suitable model was 2-compartment model. Furthermore, we analyzed the pharmacokinetics of meropenem in critically ill patients with acute kidney injury treated with continuous hemodiafiltration. Our results indicated that a meropenem dosage of 0.5 g every 8 hours or 1 g every 12 hours was suitable in this population. The protocol enabled to achieve 100% time above the minimum inhibitory concentration for bacteria with a minimum inhibitory concentration less than 2 mg/L.
|
